We are live on ! Find out more
GEVA

SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA

Delisted

GEVA was delisted on the 22nd of June, 2015.

Back to rankings

0 hedge funds and large institutions have $0 invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2015 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 130 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 130 → 0 (-130)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less capital invested

Capital invested by funds: $3.89B → $0 (-$3.89B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 130

Holders
–
Holders Change
-130
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
130
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$1.14B
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$541M
3
Capital Research Global Investors
Capital Research Global Investors
California
-$442M
4
CWAM
Columbia Wanger Asset Management
Illinois
-$317M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$152M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
76
BlackRock Group
United Kingdom
– -$929K -9,522 Closed
DCM
77
Dupont Capital Management
Delaware
– -$815K -8,360 Closed
Public Employees Retirement Association of Colorado
78
Public Employees Retirement Association of Colorado
Colorado
– -$745K -7,634 Closed
PPA
79
Parametric Portfolio Associates
Washington
– -$737K -7,556 Closed
Nomura Asset Management
80
Nomura Asset Management
Japan
– -$683K -7,000 Closed
Susquehanna International Group
81
Susquehanna International Group
Pennsylvania
– -$677K -6,944 Closed
PC
82
Polar Capital
United Kingdom
– -$671K -6,881 Closed
GH
83
GAM Holding
Switzerland
– -$624K -6,400 Closed
SIA
84
Sit Investment Associates
Minnesota
– -$568K -5,825 Closed
USAA
85
United Services Automobile Association
Texas
– -$454K -4,650 Closed
Legal & General Group
86
Legal & General Group
United Kingdom
– -$402K -4,114 Closed
TAM
87
Tocqueville Asset Management
New York
– -$383K -3,925 Closed
Principal Financial Group
88
Principal Financial Group
Iowa
– -$365K -3,744 Closed
Group One Trading
89
Group One Trading
Illinois
– -$359K -3,677 Closed
PPCM
90
Pillar Pacific Capital Management
California
– -$346K -3,550 Closed
PP
91
Paloma Partners
Connecticut
– -$332K -3,400 Closed
AQR Capital Management
92
AQR Capital Management
Connecticut
– -$322K -3,300 Closed
M&T Bank
93
M&T Bank
New York
– -$315K -3,232 Closed
SM
94
Sabby Management
Florida
– -$294K -3,013 Closed
Bank of America
95
Bank of America
North Carolina
– -$268K -2,746 Closed
Prudential Financial
96
Prudential Financial
New Jersey
– -$251K -2,570 Closed
CSS
97
Cubist Systematic Strategies
Connecticut
– -$239K -2,447 Closed
CIM
98
CenturyLink Investment Management
Colorado
– -$235K -2,411 Closed
CCMH
99
Cornerstone Capital Management Holdings
New York
– -$234K -2,400 Closed
AB
100
Amalgamated Bank
New York
– -$228K -2,333 Closed
2 3
4
5 6

GEVA Hedge Fund Activity: Q2 2015 in Review

0 of the 3,713 institutional investors tracked by Wall St. Rank reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) for Q2 2015, worth a combined $0 — down 100% from $3.89B a quarter earlier.

Sellers outnumbered buyers: 130 funds closed out of GEVA and 0 opened new positions — a net loss of 130 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.14B sold.

  • 0 institutional investors held SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) as of Q2 2015, down from 130 in Q1 2015.
  • Funds reported $0 of SYNAGEVA BIOPHARMA CORP COM STK (DE) stock for Q2 2015, down 100% quarter-over-quarter.
  • 0 funds opened new SYNAGEVA BIOPHARMA CORP COM STK (DE) positions in Q2 2015 and 130 closed out, a net change of -130 holders.
  • The largest SYNAGEVA BIOPHARMA CORP COM STK (DE) seller in Q2 2015 was Baker Bros. Advisors, an estimated $1.14B sold.

Based on aggregated 13F filings for Q2 2015.